APA (7th ed.) Citation

N, G., S, B., F, W., T, K., L, O., E, B., . . . G, M. (2026). In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis. Science translational medicine, 18(833), eads0633. https://doi.org/10.1126/scitranslmed.ads0633

Chicago Style (17th ed.) Citation

N, Gacem, et al. "In Silico Screening and Preclinical Validation Identify Bavisant as a Therapeutic Candidate for Multiple Sclerosis." Science Translational Medicine 18, no. 833 (2026): eads0633. https://doi.org/10.1126/scitranslmed.ads0633.

MLA (9th ed.) Citation

N, Gacem, et al. "In Silico Screening and Preclinical Validation Identify Bavisant as a Therapeutic Candidate for Multiple Sclerosis." Science Translational Medicine, vol. 18, no. 833, 2026, p. eads0633, https://doi.org/10.1126/scitranslmed.ads0633.